156.245 0.055 (0.04%) | 02-19 14:24 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() ![]() ![]() |
|||
Targets | 6-month : | 183.8 | 1-year : | 214.68 |
Resists | First : | 157.36 | Second : | 183.8 |
Pivot price | 130.97 ![]() |
|||
Supports | First : | 133.05 | Second : | 118.02 |
MAs | MA(5) : | 144.81 ![]() |
MA(20) : | 130.16 ![]() |
MA(100) : | 131.95 ![]() |
MA(250) : | 135.44 ![]() |
|
MACD | MACD : | 3.9 ![]() |
Signal : | 0 ![]() |
%K %D | K(14,3) : | 93 ![]() |
D(3) : | 86 ![]() |
RSI | RSI(14): 70.7 ![]() |
|||
52-week | High : | 161 | Low : | 111.08 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ASND ] has closed above the upper band by 0.2%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 176.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
If tomorrow: | Open lower | Open higher |
High: | 157.46 - 157.93 | 157.93 - 158.45 |
Low: | 143.66 - 144.2 | 144.2 - 144.8 |
Close: | 155.18 - 156.04 | 156.04 - 157.01 |
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Wed, 19 Feb 2025
Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $260.00 at Evercore ISI - MarketBeat
Tue, 18 Feb 2025
Rice Hall James & Associates LLC Has $22.56 Million Stock Holdings in Ascendis Pharma A/S (NASDAQ:ASND) - MarketBeat
Sun, 16 Feb 2025
Ascendis Pharma A/S (NASDAQ:ASND) Given New $168.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Sun, 16 Feb 2025
Ascendis Pharma A/S (NASDAQ:ASND) Issues Earnings Results - MarketBeat
Sat, 15 Feb 2025
Ascendis Pharma A/S (NASDAQ:ASND) Yearly Results: Here's What Analysts Are Forecasting For This Year - Simply Wall St
Thu, 13 Feb 2025
Ascendis Pharma A/S Earnings Call Highlights Growth and Challenges - TipRanks
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 60 (M) |
Shares Float | 59 (M) |
Held by Insiders | 0.7 (%) |
Held by Institutions | 110.6 (%) |
Shares Short | 3,290 (K) |
Shares Short P.Month | 3,420 (K) |
EPS | -6.79 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | -1.77 |
Profit Margin | -104 % |
Operating Margin | 0.2 % |
Return on Assets (ttm) | -17.4 % |
Return on Equity (ttm) | 0 % |
Qtrly Rev. Growth | 26.2 % |
Gross Profit (p.s.) | 5.33 |
Sales Per Share | 6.07 |
EBITDA (p.s.) | -4.58 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -306 (M) |
Levered Free Cash Flow | -200 (M) |
PE Ratio | -22.86 |
PEG Ratio | 0 |
Price to Book value | -87.68 |
Price to Sales | 25.53 |
Price to Cash Flow | -30.33 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |